Latest from Perlmutter Cancer Center at NYU Langone

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the efficacy and safety of the trastuzumab (Herceptin) biosimilar candidate CT-P6 in HER2-positive breast cancer.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Robert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses remaining questions with immunotherapy in bladder cancer.
 

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care^® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.
 

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer screening techniques.
 

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.